Literature DB >> 30952657

Tissue-Specific Oncogenic Activity of KRASA146T.

Asim K Bera1, Jia Lu1, Emily J Poulin2,3, Yi-Jang Lin2,3, Samantha Dale Strasser2,4,5, Joao A Paulo6, Tannie Q Huang7, Carolina Morales7, Wei Yan1, Joshua Cook2,3, Jonathan A Nowak8, Douglas K Brubaker2,3,4, Brian A Joughin9, Christian W Johnson2,3, Rebecca A DeStefanis2,3, Phaedra C Ghazi2,3, Sudershan Gondi1, Thomas E Wales10, Roxana E Iacob10, Lana Bogdanova7, Jessica J Gierut2,3, Yina Li2,3, John R Engen10, Pedro A Perez-Mancera11, Benjamin S Braun7, Steven P Gygi6, Douglas A Lauffenburger4, Kenneth D Westover12, Kevin M Haigis13,3,14.   

Abstract

KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRASG12D, a common mutant form, and KRASA146T, a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRASA146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor-induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRASG12D and KRASA146T exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer. SIGNIFICANCE: Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.See related commentary by Hobbs and Der, p. 696.This article is highlighted in the In This Issue feature, p. 681. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30952657      PMCID: PMC6548671          DOI: 10.1158/2159-8290.CD-18-1220

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  54 in total

1.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Authors:  David A Tuveson; Alice T Shaw; Nicholas A Willis; Daniel P Silver; Erica L Jackson; Sandy Chang; Kim L Mercer; Rebecca Grochow; Hanno Hock; Denise Crowley; Sunil R Hingorani; Tal Zaks; Catrina King; Michael A Jacobetz; Lifu Wang; Roderick T Bronson; Stuart H Orkin; Ronald A DePinho; Tyler Jacks
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

2.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.

Authors:  L Johnson; K Mercer; D Greenbaum; R T Bronson; D Crowley; D A Tuveson; T Jacks
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

Review 3.  Fluorescence approaches to the study of the p21ras GTPase mechanism.

Authors:  J F Eccleston; K J Moore; G G Brownbridge; M R Webb; P N Lowe
Journal:  Biochem Soc Trans       Date:  1991-04       Impact factor: 5.407

4.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 5.  Hydrogen exchange mass spectrometry for the analysis of protein dynamics.

Authors:  Thomas E Wales; John R Engen
Journal:  Mass Spectrom Rev       Date:  2006 Jan-Feb       Impact factor: 10.946

6.  Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection.

Authors:  M H Wong; J R Saam; T S Stappenbeck; C H Rexer; J I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

7.  Recurrent KRAS codon 146 mutations in human colorectal cancer.

Authors:  Sarah Edkins; Sarah O'Meara; Adrian Parker; Claire Stevens; Marcelo Reis; Siân Jones; Chris Greenman; Helen Davies; Gillian Dalgliesh; Simon Forbes; Chris Hunter; Raffaella Smith; Philip Stephens; Peter Goldstraw; Andrew Nicholson; Tsun Leung Chan; Victor E Velculescu; Siu Tsan Yuen; Suet Yi Leung; Michael R Stratton; P Andrew Futreal
Journal:  Cancer Biol Ther       Date:  2006-08-01       Impact factor: 4.742

8.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Authors:  Sunil R Hingorani; Emanuel F Petricoin; Anirban Maitra; Vinodh Rajapakse; Catrina King; Michael A Jacobetz; Sally Ross; Thomas P Conrads; Timothy D Veenstra; Ben A Hitt; Yoshiya Kawaguchi; Don Johann; Lance A Liotta; Howard C Crawford; Mary E Putt; Tyler Jacks; Christopher V E Wright; Ralph H Hruban; Andrew M Lowy; David A Tuveson
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

9.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

10.  Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

Authors:  Kevin M Haigis; Krystle R Kendall; Yufang Wang; Ann Cheung; Marcia C Haigis; Jonathan N Glickman; Michiko Niwa-Kawakita; Alejandro Sweet-Cordero; Judith Sebolt-Leopold; Kevin M Shannon; Jeffrey Settleman; Marco Giovannini; Tyler Jacks
Journal:  Nat Genet       Date:  2008-03-30       Impact factor: 38.330

View more
  56 in total

1.  A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.

Authors:  Konstantin Budagyan; Jonathan Chernoff
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Inhibition of Nonfunctional Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Vadim Gaponenko
Journal:  Cell Chem Biol       Date:  2021-01-12       Impact factor: 8.116

3.  Ras Variant Biology and Contributions to Human Disease.

Authors:  Ian Prior
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.

Authors:  Dongsung Kim; Jenny Yaohua Xue; Piro Lito
Journal:  Cell       Date:  2020-10-15       Impact factor: 41.582

Review 5.  The duality of human oncoproteins: drivers of cancer and congenital disorders.

Authors:  Pau Castel; Katherine A Rauen; Frank McCormick
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 60.716

6.  Structural basis of the atypical activation mechanism of KRASV14I.

Authors:  Asim K Bera; Jia Lu; Thomas E Wales; Sudershan Gondi; Deepak Gurbani; Andrew Nelson; John R Engen; Kenneth D Westover
Journal:  J Biol Chem       Date:  2019-07-24       Impact factor: 5.157

Review 7.  Not all cancers are created equal: Tissue specificity in cancer genes and pathways.

Authors:  Joy J Bianchi; Xin Zhao; Joseph C Mays; Teresa Davoli
Journal:  Curr Opin Cell Biol       Date:  2020-02-21       Impact factor: 8.382

8.  Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.

Authors:  Yan Liu; Fleur M Ferguson; Lianbo Li; Miljan Kuljanin; Caitlin E Mills; Kartik Subramanian; Wayne Harshbarger; Sudershan Gondi; Jinhua Wang; Peter K Sorger; Joseph D Mancias; Nathanael S Gray; Kenneth D Westover
Journal:  Cell Chem Biol       Date:  2020-08-04       Impact factor: 8.116

9.  GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRASP34R.

Authors:  Asim K Bera; Jia Lu; Chunya Lu; Lianbo Li; Sudershan Gondi; Wei Yan; Andrew Nelson; Goujun Zhang; Kenneth D Westover
Journal:  Birth Defects Res       Date:  2020-03-18       Impact factor: 2.344

Review 10.  The Frequency of Ras Mutations in Cancer.

Authors:  Ian A Prior; Fiona E Hood; James L Hartley
Journal:  Cancer Res       Date:  2020-03-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.